Clinical Trials · NCT03373708
Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer
- Phase
- Phase 2/Phase 3
- Recruitment status
- Unknown
- Sponsor
- Zhiyong Yu
- Enrollment
- 200
- Start date
- Dec 2017
- Locations
- See registry
- Primary endpoint
- Disease-free survival (DFS)